DURHAM, N.C.—Heat Biologics Inc. closed the quarter with the presentation of preclinical data from its ComPACT platform at the 2016 Society for Immunotherapy of Cancer Annual Meeting. The platform is a single product that combines Heat’s ImPACT therapeutic vaccine with an immune co-stimulatory molecule. The poster presented at the meeting evaluated ComPACT/OX40L in a third preclinical mouse tumor model, specifically colorectal cancer. ComPACT/OX40L was found to amplify antigen-specific CD8+ T cells and memory precursor effector cells, block tumor growth and increase tumor rejection and animal survival. In addition, it lacked the broad systemic inflammation seen with OX40 antibody therapy and when combined with PD1 or PD-L1 blocking antibodies, triggered greater antitumor immunity than either compound alone. Previous ComPACT studies have found that this program also demonstrates antitumor efficacy in mouse models of colon cancer and melanoma.